Structure-based design of thrombin inhibitors

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 4, 2003, Pages 437-450

  Pfau, Roland ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Antithrombotics; Factor IIa; Structure based design; Thrombin; Thrombin inhibitor; Thrombosis

Indexed keywords

ARGATROBAN; ARGININE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZYLAMINE DERIVATIVE; BMS 184919; BMS 189090; BMS 189664; BMS 191032; DABIGATRAN; DABIGATRAN ETEXILATE; PIPERIDINE DERIVATIVE; PROTEIN INHIBITOR; PYRIDAZINE DERIVATIVE; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; TARTARIC ACID DERIVATIVE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; DRUG INDUSTRY; DRUG RECEPTOR BINDING; DRUG RESEARCH; HUMAN; HYDROGEN BOND; MOLECULAR MIMICRY; MOLECULAR MODEL; PHARMACOPHORE; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SUBSTITUTION REACTION; THROMBOEMBOLISM; X RAY ANALYSIS;

ANTICOAGULANTS; BICYCLO COMPOUNDS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; MODELS, MOLECULAR; MOLECULAR MIMICRY; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPLATES, GENETIC; THROMBIN;

EID: 0043031346     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Weitz JI, Crowther M: Direct thrombin Inhibitors. Thromb Res (2002) 106(3):V275-V284. A comparison of the therapeutic use and limitations of thrombin inhibitors currently available.
2. Steinmetzer T, Hauptmann J, Stürzebecher J: Advances in the development of thrombin inhibitors. Expert Opin Investig Drugs (2001) 10(5):845-864. A concise and detailed review covering the development of thrombin inhibitors up to 2001.
3. Coburn CA: Small-molecule direct thrombin inhibitors: 1997-2000. Exp Opin Ther Pat (2001) 11(5):721-738. A detailed review covering the patent literature on thrombin inhibitors from 1997 to 2000.
4. 2Cl - A selective affinity label for thrombin. Thromb Res (1979) 14(6):969-973.
5. Das J, Kimball SD: Thrombin active site inhibitors. Bioorg Med Chem (1995) 3(8):999-1007.
6. Danilewicz JC, Abel SM, Brown AD, Fish PV, Hawkeswood E, Holland SJ, James K, McElroy AB, Overington J, Powling MJ, Rance DJ: Design of selective thrombin inhibitors based on the (R)-Phe-Pro-Arg sequence. J Med Chem (2002) 45(12):2432-2453. An interesting paper focusing on the peptidomimetic design of a potent thrombin inhibitor.
7. Iwanowicz EJ, Kimball SD, Lin J, Lau WF, Han WC, Wang TC, Roberts DG, Schumacher WA, Ogletree ML, Seiler SM: Retro-binding thrombin active site inhibitors: Identification of an orally active inhibitor of thrombin catalytic activity. Bioorg Med Chem Lett (2002) 12(21):3183-3186.
8. Nishio M, Umezawa Y, Hirota M, Takeuchi Y: The CH/π interaction: Significance in molecular recognition. Tetrahedron (1995) 51(32):8665-8701.
9. Edwards PD, Mauger RC, Cottrell KM, Morris FX, Pine KK, Sylvester MA, Scott CW, Furlong ST: Synthesis and enzymatic evaluation of a P1 amidine aminocoumarin substrate library for trypsin-like serine proteases. Bioorg Med Chem Lett (2000) 10(20):2291-2294.
10. Furlong ST, Mauger RC, Strimpler AM, Liu YP, Morris FX, Edwards PD: Synthesis and physical characterization of a P1 arginine combinatorial library, and its application to the determination of the substrate specificity of serine peptidases. Bioorg Med Chem (2002) 10(11):3637-3647.
11. Clement CC: Structure-activity relationships for synthetic peptide inhibitors of thrombin. 225th ACS National Meeting, New Orleans, LA, USA (2003):MEDI 228.
12. Hilpert K, Ackermann J, Banner DW, Gast A, Gubernator K, Hadváry P, Labler L, Muller K, Schmid G, Tschopp T, van der Waterbeemd H: Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem (1994) 37(23):3889-3901.
13. Chen Z, Li Y, Mulichak AM, Lewis SD, Shafer JA: Crystal structure of human α-thrombin complexed with hirugen and p-amidinophenylpyruvate at 1. 6 Å resolution. Arch Biochem Biophys (1995) 322(1):198-203.
14. Das J, Kimball D, Reid JA, Wang TC, Lau WF, Roberts DG, Seiler SM, Schumacher WA, Ogletree ML: Thrombin active site inhibitors: Chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues. Bioorg Med Chem Lett (2002) 12(1):41-44.
15. Das J, Kimball D, Hall SE, Han WC, Iwanowicz E, Lin J, Moquin RV, Reid JA, Sack JS, Malley MF, Chiehying YC et al. Molecular design and structure-activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664. Bioorg Med Chem Lett (2002) 12(1):45-49. A thorough analysis of SAR within this structural class.
16. Dahlgren A, Brånalt J, Kvarnström I, Nilsson I, Musil D, Samuelsson B: Synthesis of potential thrombin inhibitors. Incorporation of tartaric acid templates as P2 proline mimetics. Bioorg Med Chem (2002) 10(5):1567-1580.
17. Thorstensson F, Kvarnström I, Musil D, Ingemar N, Samuelsson B: Synthesis of novel thrombin inhibitors. Use of ring-closing metathesis reactions for synthesis of P2 cyclopentene- and cyclohexenedicarboxylic acid derivatives. J Med Chem (2003) 46(7):1165-1179. Interesting approach for mimicking the Pro-based scaffold.
18. Guimarães CR, Bicca de Alencastro R: Thrombin inhibition by novel benzamidine derivatives: A free-energy perturbation study. J Med Chem (2002) 45(23):4995-5004.
19. Adang AE, de Man AP, Vogel GM, Grootenhuis PD, Smit MJ, Peters CA, Visser A, Rewinkel JB, Van Dinther T, Lucas J, Kelder J et al: Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics. J Med Chem (2002) 45(20):4419-4432. An interesting approach for improving bioavailability.
20. Lee VH: Membrane transporters. J Pharm Sci (2000) 11(Suppl 2):S41-S50.
21. Ranadive SA, Chen AX, Serajuddin AT: Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm Res (1992) 9(11):1480-1486.
22. Peterlin-Mašič L, Mlinšek G, Šolmajer T, Trampuš-Bakija A, Stegnar M, Kikelj D: Novel thrombin inhibitors incorporating non-basic partially saturated heterobicyclic P1-arginine mimetics. Bioorg Med Chem Lett (2003) 13(5):789-794. This article describes the extensive use of Arg-mimetics for enhancing bioavailability.
23. Katz BA, Spencer JR, Elrod K, Luong C, Mackman RL, Rice M, Sprengeler PA, Allen D, Janc J: Contribution of multicentered short hydrogen bond arrays to potency of active site-directed serine protease inhibitors. J Am Chem Soc (2002) 124(39):11657-11668.
24. Lee K, Jung WH, Park CW, Park HD, Lee SH, Kwon OH: Noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1. Bioorg Med Chem Lett (2002) 12(7)1017-1022. A thorough analysis of amidine derivatives providing crystallographic data.
25. Lange UE, Zechel C: Solid-phase synthesis of thrombin inhibitors. Bioorg Med Chem Lett (2002) 12(12):1571-1573.
26. Lévesque S, St-Denis Y, Bachand B, Préville P, Leblond L, Winocour PD, Edmunds JJ, Rubin JR, Siddiqui MA: Novel bicyclic lactam inhibitors of thrombin: Potency and selectivity optimization through P1 residues. Bioorg Med Chem Lett (2001) 11(24):3161-3164. The use of a central scaffold structurally different from the natural substrate, and use of Arg mimetics are described. A complementary article (see reference [27]) has been published by these authors.
27. St-Denis Y, Lévesque S, Bachand B, Edmunds JJ, Leblond L, Préville P, Tarazi M, Winocour PD, Siddiqui MA: Novel bicyclic lactam inhibitors of thrombin: Highly potent and selective inhibitors. Bioorg Med Chem Lett (2002) 12(8):1181-1184. The use of a central scaffold structurally different from the natural substrate, and use of Arg mimetics are described. This review complements an article previously published by these authors (see reference [26]).
28. Tucker TJ, Brady SF, Lumma WC, Lewis SD, Gardell SJ, Naylor-Olsen AM, Yan Y, Sisko JT, Stauffer KJ, Lucas BJ, Lynch JJ et al: Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. J Med Chem (1998) 41(17):3210-3219.
29. Mathew J, Farber K, Nakanishi H, Qabar M: Asymmetric synthesis and conformational analysis of the two enantimers of the saturated analog of the potent thrombin inhibitor MOL-376. Tetrahedron Lett (2003) 44(3):583-586. Another elegant approach to the variation of the central scaffold.
30. Edwards PD, Andisik DW, Strimpler AM, Gomes B, Tuthill PA: Nonpeptidic inhibitors of human neutrophil elastase. 7. Design, synthesis and in vitro activity of a series of pyridopyrimidine trifluoromethyl ketones. J Med Chem (1996) 39(5):1112-1124.
31. Sanderson PE, Dyer DL, Naylor-Olsen AM, Vacca JP, Gardell SJ, Lewis SD, Lucas BJ Jr, Lyle EA, Lynch JJ Jr, Mulichak AM: L-373,890, an achiral, noncovalent, subnanomolar thrombin inhibitor. Bioorg Med Chem Lett (1997) 7(12):1497-1500.
32. Sanderson PE, Cutrona KJ, Dyer DL, Krueger JA, Kuo LC, Lewis SD, Lucas BJ, Yan Y: Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'. Bioorg Med Chem Lett (2003) 13(2):161-164. An interesting approach to find the minimum requirements for thrombin inhibition.
33. Nantermet PG, Selnick HG: Potent thrombin inhibitors via a 20-membered ring olefin metathesis macrocyclization. Tetrahedron Lett (2003) 44(11):2401-2404. An interesting approach for restricting conformational freedom.
34. Burgey CS, Robinson KA, Lyle TA, Sanderson PE, Lewis SD, Lucas BJ, Krueger JA, Singh R, Miller-Stein C, White RB, Wong B et al: Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines. J Med Chem (2003) 46(4):461-473. A thorough analysis and well-structured metabolic stabilization strategy; potency is maintained by utilizing weakly basic or neutral P1 residues.
35. Hunter CA, Sanders JK: The nature of π-π interactions. J Am Chem Soc (1990) 112(14):5525-5534.
36. Singh R, Elipe MV, Pearson PG, Arison BH, Wong BK, White R, Yu X, Burgey CS, Lin JH, Baillie TA: Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins. Chem Res Toxicol(2003) 16(2):198-207.
37. Burgey CS, Robinson KA, Lyle TA, Nantermet PG, Selnick HG, Isaacs RC, Lewis SD, Lucas BJ, Krueger JA, Singh R, Miller-Stein C et al: Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides. Bioorg Med Chem Lett (2003) 13(7):1353-1357. An elegant approach for fast access to compounds with improved bioavailability.
38. Sanderson PE, Cutrona KJ, Savage KL, Naylor-Olsen AM, Bickel DJ, Bohn DL, Clayton FC, Krueger JA, Lewis SD, Lucas BJ, Lyle EA et al: 3-Amino-4-sulfonylpyridinone acetamide and related pyridothlazine pyridothiazine thrombin inhibitors. Bioorg Med Chem Lett (2003) 13(8):1441-1444.
39. Blagg J: Thrombin inhibitors. Medical Chemistry - Rist Anglo-Swedish Symposium, Are Fjallby, Sweden (2003).
40. Minami NK, Reiner JE, Semple JE: Asymmetric synthesis of novel quarternary α-hydroxy-δ-lactam dipeptide surrogates. Bioorg Med Chem Lett (1999) 9(17):2625-2628.
41. Reiner JE, Lim-Wilby MS, Brunck TK, Uong TH, Goldman EA, Abelman MA, Nutt RF, Semple JE, Tamura SY: Investigation of the S3-site of thrombin: Design, synthesis and biological activity of 4-substituted 3-amino-2-pyridones incorporating P1-argininals. Bioorg Med Chem Lett (1999) 9(6):895-900.
42. Reiner JE, Siev DV, Araldi GL, Cui JJ, Ho JZ, Reddy KM, Mamedova L, Vu PH, Lee KS, Minami NK, Gibson TS et al: Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-monocyclic arginine surrogates. Bioorg Med Chem Lett (2002) 12(8):1203-1208. A thorough analysis of an SAR study utilizing Arg mimetics. Reference [43] complements this review.
43. Cui JJ, Araldi GL, Reiner JE, Reddy KM, Kemp SJ, Ho JZ, Siev DV, Mamedova L, Gibson TS, Gaudette JA, Minami NK et al: Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-bicyclic arginine surrogates. Bioorg Med Chem Lett (2002) 12(20):2925-2930. A thorough analysis of an SAR study utilizing Arg mimetics. This review complements reference [42].
44. Ho JZ, Gibson TS, Semple JE: Novel, potent non-covalent thrombin inhibitors incorporating P3-lactam scaffolds. Bioorg Med Chem Lett (2002) 12(5):743-748. Interesting scaffold variation mimicking the Gly-Pro unit.
45. Semple JE, Levy OE, Minami NK, Owens TD, Siev DV: Novel potent and selective chimeric FXa inhibitors featuring hydrophobic P1-ketoamide moieties. Bioorg Med Chem Lett (2000) 10(20):2305-2309.
46. Tamura SY, Levy OE, Uong TH, Reiner JE, Goldman EA, Ho JZ, Cohen CR, Bergum PW, Nutt RF, Brunck TK, Semple JE: Guanylpiperidine peptidomimetics: Potent and selective bis-cation inhibitors of Factor Xa. Bioorg Med Chem Lett (2000) 10(8):745-749.
47. Lu T, Soll RM, Illig CR, Bone R, Murphy L, Spurlino J, Salemme FR, Tomczuk BE: Structure-activity and crystallographic analysis of a new class of non-amide based thrombin inhibitor. Bioorg Med Chem Lett (2000) 10(1):79-82.
48. Greenidge PA, Mérette SA, Beck R, Dodson G, Goodwin CA, Scully MF, Spencer J, Weiser J, Deadman JJ: Generation of ligand conformations in continuum solvent consistent with protein active site topology: Application to thrombin. J Med Chem (2003) 46(8):1293-1305. An interesting approach based on crystallographic data and molecular modeling.
49. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W: Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem (2002) 45(9):1757-1766. Thorough analysis of an inhibitor based on a scaffold that is structurally different from the natural substrate.
50. PFIZER (Blagg J, Brown AD, Gautier EC, Smith JD, McElroy AB): Preparation of heterocyclic compounds as antithrombotic agents. US-06417203 (2002).